Aldeyra therapeutics, inc. (ALDX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Operating expenses:
Research and development

44,351

29,823

16,302

13,175

7,574

3,707

1,541

Acquired in-process research and development

6,567

-

-

-

-

-

-

General and administrative

12,154

9,876

6,185

5,520

4,414

3,563

2,134

Loss from operations

-63,074

-39,699

-22,488

-18,695

-11,989

-7,270

-3,676

Other income (expense):
Change in fair value of preferred stock warrant liabilities

-

-

-

-

-

-2,327

-720

Change in fair value of convertible preferred stock rights and rights option liabilities

-

-

-

-

-

-

16,175

Interest income

1,541

952

261

102

11

0

0

Interest expense

603

146

113

105

112

244

159

Total other income (expense), net

937

805

147

-3

-101

2,083

16,736

Loss before income taxes

-62,136

-38,893

-

-

-

-

-

Income tax benefit

-1,309

-

-

-

-

-

-

Net loss

-60,826

-38,893

-22,340

-18,699

-12,090

-5,187

13,060

Net loss per share - basic and diluted

-2.24

-1.79

-1.40

-1.65

-1.40

-

-

Weighted average common shares outstanding - basic and diluted

27,111

21,685

15,921

11,352

8,633

-

-

Accretion of preferred stock

-

-

-

-

-

333

822

Deemed dividend

-

-

-

-

-

4,053

-

Allocation of undistributed earnings to preferred stockholders

-

-

-

-

-

-

11,128

Net loss attributable to common stockholders

-

-

-

-

-

-9,573

1,109

Basic

-

-

-

-

-

-2.51

3.49

Diluted

-

-

-

-

-

-3.09

-17.61

Basic

-

-

-

-

-

3,818

318

Diluted

-

-

-

-

-

3,850

855